SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
(RULE 13D-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(A)
Tech Laboratories, Inc.
(NAME OF ISSUER)
COMMON STOCK, $0.01 PAR VALUE PER SHARE
(TITLE OF CLASS OF SECURITIES)
878249101
(CUSIP NUMBER)
Craig H. Effrain
Stursberg & Veith
405 Lexington Avenue, Suite 4949
Mew York, New York 10174
212-922-1177
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE NOTICES AND
COMMUNICATIONS)
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
February 1, 2003 & January 30, 2003
(vesting of options)
IF THE FILING PERSON HAS PREVIOUSLY FILED A STATEMENT ON SCHEDULE 13G TO REPORT
THE ACQUISITION WHICH IS THE SUBJECT OF THIS SCHEDULE 13D, AND IS FILING THIS
SCHEDULE BECAUSE OF RULE 13D-1(E), 13D-1(F) OR 13D-1(G), CHECK THE FOLLOWING BOX
/ /.
NOTE: SCHEDULES FILED IN PAPER FORMAT SHALL INCLUDE A SIGNED ORIGINAL AND FIVE
COPIES OF THE SCHEDULE, INCLUDING ALL EXHIBITS. SEE RULE 13D-7 FOR OTHER
PARTIES TO WHOM COPIES ARE TO BE SENT.
* THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON'S
INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND
FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER
DISCLOSURES PROVIDED IN A PRIOR COVER PAGE.
THE INFORMATION REQUIRED ON THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED
TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF
1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT
BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE
NOTES).
SCHEDULE 13D
CUSIP NO
---------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Bernard M. Ciongoli, 154-36-6764
---------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A (A) / /
MEMBER OF A GROUP (SEE INSTRUCTIONS) (B) / /
---------------------------------------------------------------------
(3) SEC USE ONLY
---------------------------------------------------------------------
(4) SOURCE OF FUNDS (SEE INSTRUCTIONS) 00
This Schedule is being filed pursuant to the vesting of certain
options previously granted to Mr. Ciongoli.
---------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL / /
PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E)
---------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION USA
---------------------------------------------------------------------
NUMBER OF SHARES (7) SOLE VOTING POWER
BENEFICIALLY
OWNED BY EACH 1,423,666
REPORTING PERSON ----------------------------------------------
WITH (8) SHARED VOTING POWER
0
----------------------------------------------
(9) SOLE DISPOSITIVE POWER
1,423,666
----------------------------------------------
(10) SHARED DISPOSITIVE POWER
0
---------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON 1,423,666
---------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) /
EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
---------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.15%
---------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN
---------------------------------------------------------------------
ITEM 1. SECURITY AND ISSUER.
This Schedule relates to the Common Stock, par value $.01 per
share, of Tech Laboratories, Inc., 955 Belmont Ave., North
Haledon, NJ 07508.
ITEM 2. IDENTITY AND BACKGROUND.
Bernard M. Ciongoli
Tech Laboratories, Inc.
955 Belmont Avenue
North Haledon, NJ 07508
Mr. Ciongoli is the president of Tech Laboratories, Inc.
None
None
USA
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
This Schedule is being filed pursuant to the vesting of options
previously granted to Mr. Ciongoli.
ITEM 4. PURPOSE OF TRANSACTION.
See Item 3.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
See Items 7 through 13 of the cover page of this Schedule. As of
the date of this Schedule, Mr. Ciongoli beneficially owned
1,423,666 shares, which includes 100,000 immediately exercisable
options at $.9625 per share, 300,000 immediately exercisable
options at $.50 per share, 300,000 immediately exercisable
options at $.43 per share, 111,000 immediately exercisable
options at $2.68125 per share, and 92,666 immediately exercisable
options at $2.4375 per share.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS, OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER.
None.
ITEM 7. MATERIALS TO BE FILED AS EXHIBITS.
None.
SIGNATURE
AFTER REASONABLE INQUIRY AND TO THE BEST OF MY KNOWLEDGE AND BELIEF, I
CERTIFY THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND
CORRECT.
DATED: April 17, 2003 /S/ Bernard M. Ciongoli
------------------------
Bernard M. Ciongoli
President, Tech Laboratories, Inc.